Sarepta Therapeutics (SRPT) Gains Ahead of FDA Decision

August 24, 2016 10:51 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Sarepta Therapeutics (NASDAQ: SRPT) is seeing strong upside Wednesday as investors continue to wait for an FDA decision on eteplirsen, which some still expect to come this month. Shares are up 6.5%.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Add Your Comment